Literature DB >> 26398831

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication.

Christina S Baik1, David Wu, Christina Smith, Renato G Martins, Colin C Pritchard.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26398831     DOI： 10.1097/JTO.0000000000000586

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  13 in total

1.  EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Authors:  Kartik Konduri; Jean-Nicolas Gallant; Young Kwang Chae; Francis J Giles; Barbara J Gitlitz; Kyle Gowen; Eiki Ichihara; Taofeek K Owonikoko; Vijay Peddareddigari; Suresh S Ramalingam; Satyanarayan K Reddy; Beth Eaby-Sandy; Tiziana Vavalà; Andrew Whiteley; Heidi Chen; Yingjun Yan; Jonathan H Sheehan; Jens Meiler; Deborah Morosini; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Siraj M Ali; Christine M Lovly
Journal:  Cancer Discov       Date:  2016-04-21       Impact factor: 39.397

2.  Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib.

Authors:  You-Cai Zhu; Wen-Xian Wang; Chun-Wei Xu; Qing-He Tan; Jian-Ying Li; Wu Zhuang; Zheng-Bo Song; Kai-Qi Du; Gang Chen; Tang-Feng Lv; Yong Song
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

3.  Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.

Authors:  Daniel B Costa
Journal:  Transl Lung Cancer Res       Date:  2016-06

4.  Role of the EGFR-KDD mutation as a possible mechanism of acquired resistance of non-small cell lung cancer to EGFR tyrosine kinase inhibitors: A case report.

Authors:  Cheng He; Yong Wang
Journal:  Mol Clin Oncol       Date:  2021-12-10

5.  Recurrent EGFR alterations in NTRK3 fusion negative congenital mesoblastic nephroma.

Authors:  Li Lei; Bradley A Stohr; Stacey Berry; Christina M Lockwood; Jessica L Davis; Erin R Rudzinski; Christian A Kunder
Journal:  Pract Lab Med       Date:  2020-05-16

Review 6.  Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer.

Authors:  Peter T Harrison; Simon Vyse; Paul H Huang
Journal:  Semin Cancer Biol       Date:  2019-09-25       Impact factor: 15.707

7.  RET rearrangements are actionable alterations in breast cancer.

Authors:  Bhavna S Paratala; Jon H Chung; Casey B Williams; Bahar Yilmazel; Whitney Petrosky; Kirstin Williams; Alexa B Schrock; Laurie M Gay; Ellen Lee; Sonia C Dolfi; Kien Pham; Stephanie Lin; Ming Yao; Atul Kulkarni; Frances DiClemente; Chen Liu; Lorna Rodriguez-Rodriguez; Shridar Ganesan; Jeffrey S Ross; Siraj M Ali; Brian Leyland-Jones; Kim M Hirshfield
Journal:  Nat Commun       Date:  2018-11-16       Impact factor: 14.919

8.  Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.

Authors:  Jinguang Wang; Xingya Li; Xingyang Xue; Qiuxiang Ou; Xue Wu; Ying Liang; Xiaonan Wang; Ming You; Yang W Shao; Zhihong Zhang; Shucai Zhang
Journal:  Int J Cancer       Date:  2018-12-16       Impact factor: 7.396

9.  Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report.

Authors:  Rui Zhong; Hui Li; Yanling Liu; Shuang Zhang; Jingjing Liu; Zhicheng Huang; Ying Cheng
Journal:  Thorac Cancer       Date:  2019-12-22       Impact factor: 3.500

10.  Durable response to EGFR tyrosine kinase inhibitors in a patient with non-small cell lung cancer harboring an EGFR kinase domain duplication.

Authors:  Esuteru Hirokawa; Satomi Watanabe; Kazuko Sakai; Masayuki Takeda; Chihiro Sato; Takayuki Takahama; Kazuto Nishio; Kazuhiko Nakagawa
Journal:  Thorac Cancer       Date:  2021-07-09       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.